Alzheimer's Disease Treatment
For older adults with clinically diagnosed Alzheimer's disease, initiate treatment with a cholinesterase inhibitor (donepezil, galantamine, or rivastigmine) for mild to moderate disease, or add memantine for moderate to severe disease, based on individualized assessment of benefits and risks 1.
Treatment Algorithm by Disease Severity
Mild to Moderate Alzheimer's Disease
Start with a cholinesterase inhibitor as first-line therapy 1, 2:
- Donepezil (5-10 mg/day)
- Galantamine (16-24 mg/day)
- Rivastigmine (6-12 mg/day oral or 9.5 mg/24hr patch)
These agents show statistically significant improvements in cognition (measured by ADAS-cog) and global assessment scores, though the clinical importance of these improvements is modest 3, 1. The evidence does not convincingly demonstrate that one cholinesterase inhibitor is superior to another 1. Withdrawal rates due to adverse effects range from 9-12%, with common side effects including nausea, dizziness, diarrhea, and agitation 1.
Direct comparison data: One 2-year trial showed rivastigmine had statistically significant advantages over donepezil in global function and activities of daily living, but with higher rates of nausea and overall adverse events 1. An 8-week trial comparing donepezil to galantamine showed no meaningful differences 1.
Moderate to Severe Alzheimer's Disease
Add memantine (20 mg/day) to the cholinesterase inhibitor, or use as monotherapy if cholinesterase inhibitors are not tolerated 1, 2. Memantine demonstrates statistically significant improvements in cognition scores and global assessment (CIBIC-plus), with limited evidence showing improvement in quality of life, caregiver burden, and resource utilization 1.
Early Alzheimer's Disease (MCI or Mild AD with Confirmed Amyloid)
Consider anti-amyloid monoclonal antibodies (lecanemab or donanemab) only in carefully selected patients with biomarker-confirmed amyloid pathology 4, 2. These represent disease-modifying therapies that show statistically significant and clinically meaningful slowing of cognitive and functional decline in early symptomatic AD 4.
Critical caveats for anti-amyloid therapy:
- Requires confirmation of amyloid pathology via CSF or PET imaging
- Mandatory APOE ε4 genotyping for risk stratification
- Intensive monitoring for amyloid-related imaging abnormalities (ARIA), which can be severe
- Real-world clinical benefit remains uncertain 4, 5
- Significant safety concerns and healthcare system readiness issues 5
Ineffective Therapies to Avoid
Do not prescribe the following, as they lack evidence of efficacy 2:
- Ginkgo biloba
- NSAIDs
- Omega-3 fatty acids
- Statins (for cognitive improvement)
Vitamin E does not improve cognition but may mitigate functional decline 2.
Behavioral Symptoms
For agitation associated with Alzheimer's disease, brexpiprazole is FDA-approved 2. First attempt nonpharmacologic interventions including music therapy, sensory stimulation, and validation therapy, which show some evidence for reducing responsive behaviors 2.
Critical Clinical Pitfalls
Avoid tacrine: Less convincing evidence and serious adverse effects make it inappropriate 1
Don't assume biomarker positivity equals clinical disease: Older adults with positive amyloid or tau biomarkers may never develop cognitive impairment or dementia 5
Co-pathology is common: Multiple pathologies frequently coexist in older adults, which influences biomarker interpretation accuracy 5
Treatment duration in trials was typically <1 year: Long-term effectiveness data remain limited 1
Outcomes measured in trials are not used in routine practice: Improvements on research instruments (ADAS-cog, CIBIC-plus) are statistically significant but often not clinically important, making interpretation of real-world benefit challenging 1
Evidence Quality Considerations
The primary treatment recommendations are based on 2008 American College of Physicians/American Academy of Family Physicians guidelines 1 that systematically reviewed cholinesterase inhibitors and memantine. While newer anti-amyloid therapies show promise 4, they remain controversial with significant safety concerns and uncertain real-world benefit 5. The traditional symptomatic therapies (cholinesterase inhibitors and memantine) remain the established standard of care with the most robust safety and efficacy data for routine clinical practice.